203 related articles for article (PubMed ID: 30143944)
1. Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.
Gudesblatt M; Wissemann K; Zarif M; Bumstead B; Fafard L; Wilken J; Blitz K; Buhse M; Santra S; Hotermans C; Lee L
CNS Drugs; 2018 Dec; 32(12):1173-1181. PubMed ID: 30143944
[TBL] [Abstract][Full Text] [Related]
2. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study.
Sundgren M; Piehl F; Wahlin Å; Brismar T
Mult Scler Relat Disord; 2016 Nov; 10():36-43. PubMed ID: 27919496
[TBL] [Abstract][Full Text] [Related]
3. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
Planche V; Moisset X; Morello R; Dumont E; Gibelin M; Charré-Morin J; Saubusse A; Mondou A; Reuter F; Defer G; Pelletier J; Brochet B; Clavelou P
J Neurol Sci; 2017 Nov; 382():148-154. PubMed ID: 29111011
[TBL] [Abstract][Full Text] [Related]
4. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.
Weinstock-Guttman B; Galetta SL; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; O'Connor PW; Phillips JT; Polman C; Stuart WH; Lynn F; Hotermans C
J Neurol; 2012 May; 259(5):898-905. PubMed ID: 22008873
[TBL] [Abstract][Full Text] [Related]
5. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study.
Mattioli F; Stampatori C; Capra R
Neurol Sci; 2011 Feb; 32(1):83-8. PubMed ID: 20872033
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.
Capra R; Morra VB; Mirabella M; Gasperini C; Scandellari C; Totaro R; De Rossi N; Masera S; Zipoli V; Patti F;
Neurol Sci; 2021 Jul; 42(7):2837-2845. PubMed ID: 33205373
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
9. Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial.
Rorsman I; Petersen C; Nilsson PC
Acta Neurol Scand; 2018 Jan; 137(1):117-124. PubMed ID: 28901547
[TBL] [Abstract][Full Text] [Related]
10. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.
Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
Pediatr Neurol; 2017 May; 70():56-60. PubMed ID: 28389054
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.
Mattioli F; Stampatori C; Bellomi F; Scarpazza C; Capra R
PLoS One; 2015; 10(7):e0131803. PubMed ID: 26148120
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
[TBL] [Abstract][Full Text] [Related]
13. Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.
Perumal J; Balabanov R; Su R; Chang R; Balcer LJ; Galetta SL; Avila RL; Rutledge D; Fox RJ
CNS Drugs; 2022 Sep; 36(9):977-993. PubMed ID: 36064841
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
[TBL] [Abstract][Full Text] [Related]
15. Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.
Iaffaldano P; Viterbo RG; Trojano M
J Neurol; 2016 Aug; 263(8):1620-5. PubMed ID: 27260295
[TBL] [Abstract][Full Text] [Related]
16. Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
Arpín EC; Sobrino TG; Vivero CD; del Campo Amigo Jorrín M; Regal AR; González JP; Bouzas ML
Neurodegener Dis Manag; 2016; 6(1):5-12. PubMed ID: 26782312
[TBL] [Abstract][Full Text] [Related]
17. The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis.
Iaffaldano P; Ruggieri M; Viterbo RG; Mastrapasqua M; Trojano M
Brain Behav Immun; 2014 Jan; 35():176-81. PubMed ID: 23994630
[TBL] [Abstract][Full Text] [Related]
18. White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
Wiebenga OT; Schoonheim MM; Hulst HE; Nagtegaal GJ; Strijbis EM; Steenwijk MD; Polman CH; Pouwels PJ; Barkhof F; Geurts JJ
AJNR Am J Neuroradiol; 2016 Jun; 37(6):1030-7. PubMed ID: 26965463
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis.
Cobo-Calvo Á; Bau L; Matas E; Romero-Pinel L; Mañé Martínez MA; Majós C; Martínez Yélamos S
Eur Neurol; 2015; 73(3-4):220-229. PubMed ID: 25792347
[TBL] [Abstract][Full Text] [Related]
20. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.
Schwid SR; Goodman AD; Weinstein A; McDermott MP; Johnson KP;
J Neurol Sci; 2007 Apr; 255(1-2):57-63. PubMed ID: 17331542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
